AU2535700A - Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation - Google Patents

Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation

Info

Publication number
AU2535700A
AU2535700A AU25357/00A AU2535700A AU2535700A AU 2535700 A AU2535700 A AU 2535700A AU 25357/00 A AU25357/00 A AU 25357/00A AU 2535700 A AU2535700 A AU 2535700A AU 2535700 A AU2535700 A AU 2535700A
Authority
AU
Australia
Prior art keywords
prophylaxis
obesity
manufacture
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25357/00A
Other languages
English (en)
Inventor
Christina Bjenning
Marit Kristiansen
Jeppe Sturis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2535700A publication Critical patent/AU2535700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU25357/00A 1999-02-12 2000-02-10 Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation Abandoned AU2535700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900188 1999-02-12
DKPA199900188 1999-02-12
PCT/DK2000/000055 WO2000047206A1 (en) 1999-02-12 2000-02-10 Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation

Publications (1)

Publication Number Publication Date
AU2535700A true AU2535700A (en) 2000-08-29

Family

ID=8090773

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25357/00A Abandoned AU2535700A (en) 1999-02-12 2000-02-10 Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation

Country Status (4)

Country Link
EP (1) EP1150674A1 (ja)
JP (1) JP2002536410A (ja)
AU (1) AU2535700A (ja)
WO (1) WO2000047206A1 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
EP1558245A2 (en) * 2002-10-28 2005-08-03 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
CA2543522A1 (en) * 2003-10-31 2005-05-12 Pfizer Products Inc. Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR100918322B1 (ko) 2003-11-12 2009-09-22 페노믹스 코포레이션 헤테로시클릭 보론산 화합물
EP1778220A1 (en) 2004-07-12 2007-05-02 Phenomix Corporation Constrained cyano compounds
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP2096111A1 (en) * 2006-11-20 2009-09-02 Japan Tobacco Inc. Pyrazoles and use thereof as drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR49M (fr) * 1959-07-27 1960-11-28 Boehringer Sohn Ingelheim Sels cristallisés de pyrrolidines substituées
GB8501438D0 (en) * 1985-01-21 1985-02-20 Fujisawa Pharmaceutical Co Pyrrolidine derivatives
IL124109A (en) * 1995-09-08 2001-10-31 Novo Nordisk As Pharmaceutical composition of 2-alkylpyrrolidines for use in the manufacture of medicaments for the treatment of diabetes
JPH09295966A (ja) * 1996-03-04 1997-11-18 Suntory Ltd ピロリジンアルカロイド化合物
UA57811C2 (uk) * 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності

Also Published As

Publication number Publication date
WO2000047206A1 (en) 2000-08-17
JP2002536410A (ja) 2002-10-29
EP1150674A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
AU2535700A (en) Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
HK1047284A1 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
AU2935200A (en) Compounds for the treatment of obesity
AU2180400A (en) A pharmaceutical combination for the treatment of depression
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
IL213809A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
TW413041U (en) Adjustable bending-bar mechanism of metal bar for surgical operation correction
AU2001272849A1 (en) Composition for the treatment of osteoarthritis
HK1047588A1 (en) 2-Amino-4H-3,1-benzoxazine-4-one derivatives for the treatment of obesity
AU2000276362A1 (en) Composition for the treatment of diabetes
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
AU1549500A (en) Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2002217866A1 (en) Geldanamycin derivatives useful for the treatment of cancer
AU2000272858A1 (en) Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments
AU3142400A (en) A pharmaceutical composition for treating angiocardiopathy and the method of producing thereof
AU2002368133A1 (en) 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
AU2002236781A1 (en) Treatment for snoring
AU5147300A (en) Orthopedic splinting article
AU7750100A (en) Method for the treatment of obesity
AU2021601A (en) Composition for the treatment of dandruff
AU1878201A (en) Composition for the treatment of damaged tissue
AU4328996A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
AU1653101A (en) Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase